Objectives
inflammation, MCI
INFLAMMATION, OXIDATIVE STRESS, SECONDARY
The main objective of the study is to compare changes in blood levels of inflammation and oxidative stress biomarkers between baseline (v0) and follow-up visits at 6 (v1) and 12 months (v2) between the study group (patients with MCI receiving treatment with 1 tablet daily of EGb 761 240 mg orally) and the control group (patients with the same clinical characteristics without treatment with EGb 761).The following were the secondary goals: (1) comparing neuropsychiatric and cognitive test scores between the study group and the control group at baseline (v0) and 12-month follow-up (v2) visits; (2) obtaining data on blood levels of inflammation and oxidative stress biomarkers after a 24-month follow-up period in both study groups; (3) evaluating changes in cognitive and neuropsychiatric test scores and blood biomarkers of oxidation and inflammation after 24 months of follow-up between the group treated with EGb761 since the beginning of the study and the group treated only with EGb761 during the last 12 months of the study (extension phase); and (4) obtaining safety data over a 2-year treatment period.